Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Nov 7, 2018 in Benign prostatic hyperplasia | 0 comments

In a nutshell

This study aimed to investigate the safety and effectiveness of silodosin (RapafloSilodyx) for the treatment of nocturia in men with benign prostatic hyperplasia (BPH). This study found that silodosin is safe and effective for the treatment of nocturia in these patients. 

Some background

People diagnosed with BPH (non-cancerous overgrowth of the prostate) or overactive bladder often experience lower urinary tract symptoms (LUTS). These can include nocturia (getting up to urinate during the night). Silodosin ?is a medication used to treat symptoms of BPH. The safety and effectiveness of silodosin for treating nocturia in men with BPH is still unclear. 

Methods & findings

This study included 112 patients with BPH. They were treated with 8 mg of silodosin daily for 12 weeks. These patients kept a diary of how many times they urinated at night while on silodosin. They also completed questionnaires on BPH symptoms at the beginning of the study, at 4 and at 12 weeks.

The number of nocturia episodes decreased at both 4 and 12 weeks of treatment. Patients also reported a quality of life improvement on questionnaires. Over 65% of patients reported a reduction of at least 25% in nocturia symptoms.

11.8% of patients experienced side effects, but these were mild, such as dry mouth or itchy skin. The most common side effect was difficulty ejaculating in 7.6% of men.  

The bottom line

This study found that silodosin is safe and effective in the treatment of nocturia in men with BPH.

The fine print

This study included a rather small number of patients. Also, there was no comparison group. Therefore, further studies are needed for more conclusive results.

Published By :


Date :

Aug 08, 2018

Original Title :

Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: A multi-center, prospective, open-label, single-arm, phase IV trial.

click here to get personalized updates